Organisation paid for research Program year 2023 Source: CMS Open Payments

Dcam Outpatient Pharmacy

Neither a doctor nor a teaching hospital

Research payments

$2,720,138

392 payments

Through program year 2023, Dcam Outpatient Pharmacy is reported as receiving $2,720,138 in research payments, across 392 payments.

By program year

3 rows

Year	Kind	Amount	Payments
2023	Research	$6,433	3
2021	Research	$1,293,527	180
2020	Research	$1,420,179	209

Breakdown

Who paid Research payments · program years 2020–2023

AbbVie, Inc. $2,684,940 368 payments
Pharmacyclics LLC, An AbbVie Company $35,198 24 payments

Studies the money was for Research payments · program years 2020–2023

A Phase 1b Dose Escalation Study Evaluating the Safety and Pharmacokinetics of Venetoclax in Combination with Azacitidine in Subjects with Treatment-Na?ve Higher-Risk Myelodysplastic Syndromes (MDS) $258,525 11 payments
M18-918 $238,787 12 payments
M15-531 $156,631 16 payments
An Open-Label, Phase 1, First-In-Human Study of TRAIL Receptor Agonist ABBV-621 in Subjects with Previously-Treated Solid Tumors and Hematologic Malignancies $146,800 3 payments
A18-877 $120,791 12 payments
Phase Ib study of the safety and efficacy of Gemtuzumab Ozogamicin and Venetoclax in patients with relapsed/refractory acute myeloid leukemia (AML), or with treatment-naive AML who are not eligible for intensive chemotherapy. $115,094 7 payments
M15-522 $102,738 9 payments
M16-415 $91,884 13 payments
A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study Comparing the Efficacy, Safety and Tolerability of ABBV-951 to Oral Carbidopa/Levodopa in Advanced Parkinsons Disease Patients $89,731 7 payments
A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Safety and Efficacy of Elezanumab when Added to Standard of Care in Relapsing Forms of Multiple Sclerosis $79,222 7 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.